Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
Date:4/18/2011

SAN FRANCISCO, April 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 25, 2011. To access the conference call, follow these instructions:Dial: (800) 573-4754 (U.S.); (617) 224-4325 (international)Passcode: 88966725 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Wednesday, May 25, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 92209339.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug cand
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... SANTA CLARA, Calif. , May 21, ... a game-changing embedded-ultrasound platform, today announced the ... Toolkit that allows complete network-based communications with ... demonstrate its latest embedded-ultrasound technology, including this ... Sao Paulo, Brazil ...
(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ... and microfluidic cell-based assay platforms, today announced the appointment ... DABT to the Company,s Board of Directors. Dr. MacDonald ... of the Schering-Plough Research Institute ("SPRI"), which was the ... acquisition by Merck & Co. in 2009. ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:5/21/2013)... CINCINNATIUsing the Department of Defense Serum Repository (DoDSR), University ... biomarkers for inflammatory bowel disease (IBD), which could help ... not yet shown symptoms. , This finding, the first ... MD, is being presented via podium presentation by staff ... Disease Week 2013, being held May 18-21 in Orlando, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
(Date:5/21/2013)... Reporter , , TUESDAY, May 21 (HealthDay News) -- Swollen ... apnea in children, and while removing them did not ... did help them with sleep, behavior and quality of ... a condition that causes abnormal pauses in breathing during ... with the surgery, and those improvements were likely responsible ...
(Date:5/21/2013)... In adults with chronic kidney disease (CKD), cigarette ... progression and transplant failure. Now, a first-of-its-kind study by ... has found a possible similar effect in children with ... , The study of 366 children aged 1 to ... of secondhand smoke exposure in CKD, according to lead ...
Breaking Medicine News(10 mins):Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 2Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 3
... men enrolled in an active surveillance program for prostate ... fared just as well as men who opted to ... during surveillance showed high-grade cancer. Active surveillance, or ... tumors are considered small, low-grade and at low risk ...
... A psychological intervention program designed for breast cancer patients reduces ... shows. The study is the latest in a series ... program that teaches patients how to cope with the disease ... survival. Researchers at Ohio State,s Comprehensive Cancer Center had ...
... guidelines for best treatment practices are common, they ... to them in clinical practice, according to a ... medicine researchers. In the study, UC associate ... his colleagues used national standards for treatment of ...
... -- City of Hope researchers received approval from the ... first-in-human study of a neural stem cell-based therapy targeting ... tumor. Karen S. Aboody, M.D., associate professor in City ... that developed this treatment strategy. Jana Portnow, M.D., assistant ...
... the University of Cincinnati (UC) and the Cincinnati ... received funding to study the care processes that ... beginning dialysis. Timmy Lee, MD, UC Health ... the study, was awarded the National Kidney Foundation,s ...
... cats have them and whales have some, too. Neurons, those ... our spinal cords to the tips of our toes, paws ... journal Cell , scientists from the Harvard Medical School, ... found a new way by which nerve cells relay information ...
Cached Medicine News:Health News:Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer 2Health News:Intervention program helps breast cancer patients live longer after recurrence 2Health News:Intervention program helps breast cancer patients live longer after recurrence 3Health News:'Knowledge translation' keeps treatment current 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 3Health News:New research examines care practices in place for dialysis patients 2
Suture Cutter, straight...
Suture Cutter, 15 Up Curve...
Suture scissor...
...
Medicine Products: